Trius Therapeutics Long Term Debt:
0.00 for Dec. 31, 2012Trius Therapeutics Historical Long Term Debt Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 0.00 |
| Dec. 31, 2012 | 0.00 |
| Sept. 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| Dec. 31, 2011 | 0.00 |
| Sept. 30, 2011 | 0.00 |
| June 30, 2011 | 0.00 |
| March 31, 2011 | 0.00 |
| Dec. 31, 2010 | 0.00 |
| Sept. 30, 2010 | 0.00 |
| June 30, 2010 | 20.16M |
| March 31, 2010 | 0.00 |
| Dec. 31, 2009 | 19.40M |
| Sept. 30, 2009 | 0.00 |
| June 30, 2009 | |
| March 31, 2009 | |
| Dec. 31, 2008 | 0.00 |
About Long Term Debt
Long-term debts are financial obligations and loans lasting longer than one year. A company must report long-term debt on its balance sheet with its date of maturity and interest rate.
Bonds and debt obligations with maturities greater than one year are examples of long-term debt. Other types of securities, including short-term notes and commercial papers usually are not long-term debt because their maturities typically are shorter than one year.
IMPORTANT: YCharts includes the Current Portion of Long Term Debt in our calculation of Long Term Debt.
Learn More
TSRX Long Term Debt Benchmarks
| Companies | |
|---|---|
| Genomic Health | 0.00 |
| Acorda Therapeutics | 1.144M |
| Exelixis | 335.74M |
TSRX Long Term Debt Rankings
| Overall |
99th percentile 1 of 7593 |
| Sector |
99th percentile 1 of 650 in Healthcare |
| Industry |
98th percentile 1 of 61 in Diagnostics & Research |
TSRX Long Term Debt Range, Past 5 Years
| Minimum | 0.00 | Dec 2008 |
| Maximum | 20.16M | Jun 2010 |
| Average | 2.473M |
TSRX News
Trius Therapeutics (TSRX) Tedizolid Phosphate Portfolio Receives NoA from UPTO
Street Insider May 13
Street Insider May 13
